Status:
COMPLETED
Efficacy and Safety of Losartan in Children With Ig A Nephropathy
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
Ministry of Food and Drug Safety, Korea
Conditions:
Glomerulonephritis, IGA
Eligibility:
All Genders
24-18 years
Phase:
PHASE3
Brief Summary
The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.
Detailed Description
Twenty nine patient with IgA nephropathy with proteinuria (urine protein to creatinine ratio \> 0.3 mg/mg) were included in the study. All patients had received losartan treatment for 24 weeks. Change...
Eligibility Criteria
Inclusion
- Age: 2years or older and younger than 18 years
- Biopsy-proven Ig A Nephropathy
- Estimated GFR ≥ 90mL/min/m\^2
- Mean urinary protein-creatinine ratio \> 0.3 g/g from three first-morning spot urine collections
Exclusion
- hypertension
- under dialysis or organ transplanted
- bilateral renal artery stenosis
- primary hyperaldosteronism
- pregnant
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2017
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT02232776
Start Date
October 1 2014
End Date
April 1 2017
Last Update
October 10 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Children's Hospital
Seoul, South Korea